Integra LifeSciences (NASDAQ:IART) Updates Q1 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its first quarter earnings guidance on Tuesday morning. The company provided EPS guidance of $0.40 to $0.45 for the period, compared to the consensus EPS estimate of $0.54. The company issued revenue guidance of $375 million to $385 million, compared to the consensus revenue estimate of $400.11 million. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on IART shares. Morgan Stanley started coverage on Integra LifeSciences in a research report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 target price on the stock. Citigroup increased their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Integra LifeSciences presently has an average rating of “Hold” and an average price target of $23.00.

Integra LifeSciences Trading Down 2.3 %

NASDAQ IART traded down $0.58 during trading on Wednesday, hitting $24.14. The stock had a trading volume of 209,393 shares, compared to its average volume of 589,260. Integra LifeSciences has a one year low of $16.81 and a one year high of $44.69. The stock has a 50 day simple moving average of $23.71 and a 200 day simple moving average of $21.83. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -268.19, a P/E/G ratio of 0.73 and a beta of 1.17. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. The firm had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period last year, the company earned $0.89 EPS. Sell-side analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current year.

Insider Activity

In related news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 3.10% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.